VERU · Veru
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $2.44
Note written ·
Price against the kill line
14.3% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $2.44, on record since 11 November 2026. The shares are down 20.5% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $2.44, the highest close of the last 20 sessions (15 October 2026), would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 June 2025, filed 12 August 2025; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 0.0
- Revenue, change on a year (%)
- −100.0
- Gross margin (%)
- 40.4
- Operating margin (%)
- −140.4
- Free cash flow, four quarters ($M)
- −26.0
- Free-cash-flow yield (%)
- −73.1
All filed numbers
What Veru reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 0.0 | −100.0 | — | — |
| first filed | 0.0 | −100.0 | — | — |
| first filed restated | 6.7 | +72.4 | 40.4 | −140.4 |
| first filed restated | 4.0 | +18.3 | 33.8 | −266.7 |
| first filed restated | 4.1 | −37.2 | 16.4 | −214.9 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −13.6 | −7.0 |
| Diluted shares, change on a year (%) | Not reported |
| Operating cash flow ($M) | −26.0 |
| Capital spending ($M) | 0.0 |
| Free cash flow ($M) | −26.0 |
| Cash and short-term investments ($M) | 23.9 |
| Debt ($M) | Not available |
| Net cash, cash less debt ($M) | Not available |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 28.4 |
| Market value ($M) | 35.6 |
| Enterprise value, market value plus net debt ($M) | Not available |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.3 |
| Free-cash-flow yield (%) | −73.1 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 8.6% of shares outstanding sold short, 4.9 days of average trading to cover, +4.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $5K | $0 |
The thesis
Veru's case rests on one clinical result: whether its oral drug enobosarm preserves lean muscle while older patients lose fat on semaglutide. The Phase 2b PLATEAU trial's 32-week interim analysis, guided to calendar Q1 2027, settles it. Until then the shares carry a going-concern warning and an open at-the-market stock-sale program, and the price has kept falling.
The story is well known: the story is well known, PLATEAU finished enrolling on 27 July 2026, and the only new company items since the 6 October 2026 WestPark Capital initiation are two 9 November 2026 releases announcing ObesityWeek presentations. The shares closed at $2.51 on 2 October 2026, $2.44 on 15 October 2026, $2.27 on 28 October 2026 and $2.12 on 10 November 2026.
The 10 November 2026 close is 49.9% below the 52-week high of $4.23 and 21.5% below the close three months earlier. The 14-day Relative Strength Index, a momentum gauge on a 0-100 scale, reads 36.4.
Veru has no revenue to confirm the story. Cash, equivalents and restricted cash were $23,880,142 at 30 June 2026 against a fiscal third-quarter net loss of $7.0 million, per the company's 10 August 2026 results release. Fiscal 2026 closed on 30 September 2026, and the annual report is the next audited look at the balance sheet.
Bullish and bearish views on Veru Inc.
The bull case on Veru Inc. (VERU), in brief: enrollment finished ahead of target. The bear case: going-concern doubt is on file.
Bull case
- Enrollment finished ahead of target. Veru's 27 July 2026 release and 10 August 2026 results report 239 PLATEAU patients against a target of roughly 200. No recruiting stands between the trial and its interim readout.
- A new QUALITY analysis is coming. Veru's 9 November 2026 release says Chief Scientific Officer Gary Barnette will give a podium talk on 16 November 2026 at ObesityWeek (14 November to 17 November 2026, Washington, DC). It covers physical function in patients 65 and older receiving a GLP-1 drug, from the Phase 2b QUALITY study.
- Novo Nordisk is supplying drug. The 2 June 2026 agreement gives Veru clinical supply of semaglutide and an exclusive right of first negotiation. The disclosed terms carry no upfront payment, milestones or equity investment.
- Patent coverage widened. The US Patent and Trademark Office issued a Notice of Allowance on 4 August 2026 for methods-of-use claims combining selective androgen receptor modulators with weight-loss drugs, with protection expected until at least 3 October 2044.
- An executive bought shares. SEC Form 4 filings show Barnette acquired 1,800 shares on 13 August 2026 at $2.6899. The close on 10 November 2026 was $2.12.
- Analyst targets sit far above the price. WestPark Capital initiated at Buy with a $28 target on 6 October 2026, per Benzinga's analyst table. MarketScreener's consensus of two analysts showed an average target of $24.50, range $10.10 to $31.50, on 6 September 2026.
Bear case
- Going-concern doubt is on file. The 10-Q for the quarter ended 30 June 2026, filed 10 August 2026, states substantial doubt about Veru's ability to continue as a going concern. The same language appeared in the 10-Q filed 13 May 2026.
- Stock sales can meet any rally. Veru's 8-K and 424B5 of 2 July 2026 set up an at-the-market program of up to $21.8 million with Oppenheimer and Canaccord at a 3.0% commission. Common shares outstanding were 16,050,320 at 31 March 2026, so the program is large against the share count. Canaccord is also a covering analyst, which makes its target a conflicted reference point.
- The upcoming talk is exploratory. The ObesityWeek presentation is a post hoc analysis of a completed trial, per Veru's 9 November 2026 release, so it adds no new randomised evidence. QUALITY enrolled 168 patients and ran 16 weeks of active treatment, per company releases.
- The interim is narrower than the trial. The 10 August 2026 release separates the 32-week lean- and fat-mass analysis by DXA scan (a body-composition X-ray) from the 68-week primary endpoint, with topline guided to calendar Q4 2027. A good interim answers the muscle question without answering the weight-loss one.
- The pipeline history is poor. Enobosarm is the former GTx ostarine, which failed in breast cancer, and the FDA rejected sabizabulin's COVID emergency-use application. The price has fallen through each of the last four reference closes since 2 October 2026.
Price setup
Veru closed at $2.12 on 10 November 2026, per adjusted daily closes. That sits $0.07 above the $2.05 52-week low and 49.9% below the $4.23 52-week high. The closes of $2.51, $2.44, $2.27 and $2.12 on four dated sessions show a steady decline with no rebound attempt.
The 14-day Relative Strength Index of 36.4 is lower than the 43.5 reading on 28 October 2026 but not yet in the below-30 range usually read as oversold. No evidence of heavy retail attention is available. The crowding signals that can be observed are the open at-the-market program, which lets the company issue shares into any rise, and an annual report expected around 17 December 2026.
The WestPark initiation on 6 October 2026 did not stop the decline, and the stock is 21.5% lower than three months ago. The shares trade well below the lowest analyst target of $10.10 in the 6 September 2026 consensus.
Catalysts ahead
- 16 November 2026: ObesityWeek podium presentation of QUALITY physical-function analysis (meeting 14 November to 17 November 2026). A post hoc look at physical function in patients 65 and older on a GLP-1 drug; it supports the enobosarm story but is not the PLATEAU result.
- ~17 December 2026 (est.): Fiscal 2026 fourth-quarter results and Form 10-K. First disclosure of at-the-market proceeds and year-end share count, and the first audited going-concern opinion since the flag appeared in May 2026.
- ~March 2027 (est.): PLATEAU 32-week interim analysis of lean and fat mass by DXA. Tests whether enobosarm preserves lean mass alongside semaglutide in patients 65 and older; it would also activate Novo's right of first negotiation.
What would change the view
A daily close above $2.44, the highest close of the last 20 sessions (15 October 2026), would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
Veru trades on its own clinical and financing events. Direction depends on the PLATEAU interim and on small-company equity-raise conditions rather than on obesity-drug leaders. Positive muscle-preservation data from Lilly's bimagrumab, Regeneron's trevogrumab or Scholar Rock's apitegromab would compete with the enobosarm story, while a Novo Nordisk move toward a negotiated deal would be the clearest outside validation. No theme cluster currently carries the name.
The evidence, claim by claim (8)
- Fiscal Q3 2026 net loss $7.0M, $(0.30) per share; cash, equivalents and restricted cash $23,880,142 at 30 June 2026. Veru fiscal Q3 2026 results release, 10 August 2026 · as of
- The Form 10-Q for the quarter ended 30 June 2026 states substantial doubt about Veru's ability to continue as a going concern. Veru Form 10-Q filed 10 August 2026 · as of
- PLATEAU is fully enrolled with 239 patients against a ~200 target; 32-week interim DXA lean and fat mass results guided to calendar Q1 2027, topline to calendar Q4 2027. Veru press release 27 July 2026; results release 10 August 2026 · as of
- At-the-market program of up to $21.8M with Oppenheimer and Canaccord Genuity at a 3.0% commission. Veru Form 8-K and Form 424B5 · as of
- Chief Scientific Officer Gary K. Barnette acquired 1,800 shares on 13 August 2026 at $2.6899. SEC Form 4 filed 17 August 2026 · as of
- WestPark Capital initiated coverage of Veru with a Buy rating and a $28 price target (analyst Ed Arce). Benzinga analyst ratings table; MarketBeat via The Stock Observer · as of
- Veru will give a podium presentation on physical function from the Phase 2b QUALITY study at ObesityWeek on 16 November 2026 in Washington, DC. Veru press release, 9 November 2026 · as of
- Veru closed at $2.12 on 10 November 2026, 49.9% below its 52-week high of $4.23; 14-day Relative Strength Index 36.4. Adjusted daily closes · as of
Sources
- Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026 · biospace.com
- Veru will present findings on older adults' physical function during weight-loss treatment · stocktitan.net
- Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress · barchart.com
- Oral agent combined with Wegovy may preserve lean mass for older adults with obesity · healio.com ·
Related · shared themes
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…
VKTX
Viking Therapeutics
Viking Therapeutics is more likely to lag the S&P 500 over three months: $960 million in cash funds its obesity Phase 3 trials, but no…
ABVX
Abivax SA
Abivax's shares are modestly more likely to beat the S&P 500 over three months because the company guides its US obefazimod ulcerative…